{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:06:12Z","timestamp":1782831972003,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ijantimicag.2020.106250","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T09:40:01Z","timestamp":1606642801000},"page":"106250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-842X","authenticated-orcid":false,"given":"Nan-Yao","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2703-7861","authenticated-orcid":false,"given":"Ching-Lung","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Shan","family":"Syue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4194-4206","authenticated-orcid":false,"given":"Ming-Chi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106250_bib0001","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to Gram-negative bacteria","volume":"362","author":"Peleg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0002","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0003","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/MD.0000000000000111","article-title":"Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy","volume":"93","author":"Girometti","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0004","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1469-0691.2011.03478.x","article-title":"Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections","volume":"18","author":"Ben-David","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1469-0691.2012.03823.x","article-title":"Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria","volume":"18","author":"Akova","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0006","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cmi.2019.04.013","article-title":"Management of carbapenem-resistant Enterobacteriaceae infections","volume":"25","author":"Durante-Mangoni","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0007","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/AAC.03007-15","article-title":"Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"60","author":"Gomez-Simmonds","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0008","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1473-3099(09)70054-4","article-title":"The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria","volume":"9","author":"Nordmann","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0009","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1001\/jama.2008.896","article-title":"Carbapenem-resistant Enterobacteriaceae: a potential threat","volume":"300","author":"Schwaber","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jmii.2016.03.003","article-title":"Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: combination of tigecycline or doxycycline and gentamicin or amikacin","volume":"52","author":"Tang","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"issue":"Supp, 3","key":"10.1016\/j.ijantimicag.2020.106250_bib0011","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/eri.12.162","article-title":"Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art","volume":"11","author":"Petrosillo","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0013","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s10096-011-1525-2","article-title":"Characterization of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream isolates at a Taiwanese hospital: clinical impacts of lowered breakpoints for carbapenems","volume":"31","author":"Lee","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0014","series-title":"Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document M100-S25","year":"2015"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0015","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. http:\/\/www.eucast.org\/clinical_breakpoints\/ [accessed 20 August 2020]."},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0016","doi-asserted-by":"crossref","first-page":"ofw132","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime-susceptible extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0017","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0018","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0019","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2020"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jac\/dkp498","article-title":"Development of a set of multiplex PCR assays for the detection of genes encoding important \u03b2-lactamases in Enterobacteriaceae","volume":"65","author":"Dallenne","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0021","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archinte.1962.03620240029006","article-title":"Gram-negative bacteremia. I. Etiology and ecology","volume":"110","author":"McCabe","year":"1962","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0924-8579(98)00060-0","article-title":"Combination antibiotic therapy versus monotherapy for Gram-negative bacteraemia: a commentary","volume":"11","author":"Chow","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0023","doi-asserted-by":"crossref","first-page":"ofv050","DOI":"10.1093\/ofid\/ofv050","article-title":"Treatment options for carbapenem-resistant Enterobacteriaceae infections","volume":"2","author":"Morrill","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0024","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/cid\/cix942","article-title":"Carbapenem-resistant Enterobacteriaceae detection practices in California: what are we missing?","volume":"66","author":"Humphries","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0025","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3201\/eid2109.150198","article-title":"Improved phenotype-based definition for identifying carbapenemase producers among carbapenem-resistant Enterobacteriaceae","volume":"21","author":"Chea","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0026","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1128\/JCM.00640-13","article-title":"Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods","volume":"51","author":"Picao","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0027","series-title":"Performance standards for antimicrobial susceptibility testing; 20th informational supplement","year":"2010"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0028","series-title":"Performance standards for antimicrobial susceptibility testing; 24th informational supplement","year":"2014"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0029","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1128\/AAC.01477-15","article-title":"Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0030","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1128\/AAC.01487-06","article-title":"Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms","volume":"51","author":"Bhat","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0031","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/jac\/dku001","article-title":"Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study","volume":"69","author":"Alves","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0032","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkl349","article-title":"Pharmacokinetic\u2013pharmacodynamic rationale for cefepime dosing regimens in intensive care units","volume":"58","author":"Roos","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0033","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jinf.2006.09.004","article-title":"Cefepime pharmacodynamics in patients with extended spectrum \u03b2-lactamase (ESBL) and non-ESBL infections","volume":"54","author":"Lee","year":"2007","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0034","doi-asserted-by":"crossref","first-page":"e00079","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-\u03b2-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodriguez-Bano","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0035","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1093\/cid\/ciaa169","article-title":"Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of Gram-negative bloodstream infections","volume":"71","author":"Amoah","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106250_bib0036","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1378\/chest.12-1920","article-title":"The pros and cons of propensity scores","volume":"142","author":"Streiner","year":"2012","journal-title":"Chest"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:38:34Z","timestamp":1760377114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920304702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0924857920304702"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106250","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106250"}}